Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZYME Stock Forecast 2026-2027
$23.26
Current Price
$1.71B
Market Cap
Buy 14
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ZYME Price Targets
+149.4%
To High Target of $58.00
+50.5%
To Median Target of $35.00
+20.4%
To Low Target of $28.00
ZYME Price Momentum
0.0%
1 Week Change
-2.8%
1 Month Change
+83.9%
1 Year Change
-11.7%
Year-to-Date Change
-21.8%
From 52W High of $29.75
+102.1%
From 52W Low of $11.51
📊 TOP ANALYST CALLS
Did ZYME Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zymeworks is one of their latest high-conviction picks.
Latest ZYME Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, ZYME has a bullish consensus with a median price target of $35.00 (ranging from $28.00 to $58.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $23.26, the median forecast implies a 50.5% upside. This outlook is supported by 14 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Andrew Berens at SVB Leerink, suggesting a 20.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZYME Analyst Ratings
14
Buy
0
Hold
0
Sell
ZYME Price Target Range
Low
$28.00
Average
$35.00
High
$58.00
Current: $23.26
Latest ZYME Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZYME.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $46.00 |
| May 8, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 9, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Mar 6, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 3, 2026 | Stifel | Buy | Maintains | $N/A | |
| Mar 3, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Dec 17, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Dec 12, 2025 | Wells Fargo | Overweight | Upgrade | $N/A | |
| Dec 3, 2025 | Citizens | Market Outperform | Initiates | $N/A | |
| Nov 21, 2025 | B. Riley Securities | Buy | Reiterates | $N/A | |
| Nov 19, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Nov 19, 2025 | Stifel | Buy | Maintains | $N/A | |
| Nov 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 7, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Oct 24, 2025 | Wells Fargo | Eva Fortea Verdejo | Equal-Weight | Assumes | $15.00 |
| Oct 16, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Oct 14, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Oct 10, 2025 | B. Riley Securities | Buy | Initiates | $N/A | |
| Aug 11, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Jul 3, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A |
Zymeworks Inc. (ZYME) Competitors
The following stocks are similar to Zymeworks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ZYME
Zymeworks
mkt cap
1.68B
Zymeworks Inc. (ZYME) Financial Data
Zymeworks Inc. has a market capitalization of $1.71B with a P/E ratio of 3.8x. The company generates $81.26M in trailing twelve-month revenue with a -126.3% profit margin.
Revenue growth is -91.1% quarter-over-quarter, while maintaining an operating margin of -1,956.7% and return on equity of -42.0%.
Valuation Metrics
Market Cap
$1.71B
Enterprise Value
$1.35B
P/E Ratio
3.8x
PEG Ratio
0.0x
Price/Sales
21.1x
Growth & Margins
Revenue Growth (YoY)
-91.1%
Gross Margin
N/A
Operating Margin
-1,956.7%
Net Margin
-126.3%
EPS Growth
-91.1%
Financial Health
Cash/Price Ratio
+21.5%
Current Ratio
10.8x
Debt/Equity
10.4x
ROE
-42.0%
ROA
-15.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zymeworks Inc. (ZYME) Business Model
About Zymeworks Inc.
What They Do
Develops biotherapeutics for cancer and autoimmune diseases.
Business Model
Zymeworks Inc. operates by innovating and developing novel multifunctional therapeutics that address unmet medical needs in oncology and immunology. The company generates revenue through strategic partnerships with leading pharmaceutical companies, leveraging its proprietary technologies to create advanced biotherapeutics that improve treatment efficacy and reduce side effects.
Additional Information
Headquartered in Canada, Zymeworks is positioned as a key player in the biotech industry, focusing on precision medicine and personalized healthcare solutions. The company's proprietary platforms, including Azymetric and EFECT technologies, are integral to its research and development efforts, enhancing the potential impact of its therapies on complex diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
273
CEO
Mr. Kenneth H. Galbraith C.A.
Country
United States
IPO Year
2017
Website
www.zymeworks.comZymeworks Inc. (ZYME) Latest News & Analysis
Latest News
Quick Summary
Zymeworks is pivoting to an oncology royalty model, with $400M in liquid assets and a $440M milestone pipeline. Zanidatamab's Priority Review could yield $265M in payments by August 2026.
Why It Matters
Zymeworks' shift to an oncology royalty model, strong balance sheet, and potential milestone payments enhance its growth prospects, appealing to risk-aware investors seeking long-term returns.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Zymeworks Inc. has authorized a $125 million share repurchase program for 2026, terminating its previous 2025 program, which repurchased 4.2 million shares for $102.3 million.
Why It Matters
Zymeworks' $125 million share repurchase program signals confidence in its financial health, potentially boosting stock value and indicating a commitment to returning capital to shareholders.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zymeworks Inc. (Nasdaq: ZYME) will participate in upcoming investor conferences, focusing on its portfolio of healthcare assets and biotherapeutics pipeline.
Why It Matters
Zymeworks' participation in investor conferences signals potential growth opportunities and increased visibility for its biotherapeutics pipeline, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Zymeworks Q1 Earnings Call Highlights
1 month ago
Quick Summary
Zymeworks (NASDAQ: ZYME) reported a wider Q1 loss with declining revenue from milestone payments, but noted regulatory catalysts for zanidatamab and progress in its pipeline.
Why It Matters
Zymeworks' wider loss and declining revenue may raise concerns about financial health, but regulatory catalysts and pipeline progress could signal future growth potential, influencing stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Zymeworks Inc. (ZYME) held its Q1 2026 earnings call, providing updates on financial performance and strategic initiatives. Full details available in the transcript.
Why It Matters
Zymeworks' Q1 earnings reveal financial health and strategic direction, impacting stock valuation and investor confidence in its growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Jazz's sBLA for zanidatamab in HER2-positive GEA received FDA Priority Review, with a target action date of August 25, 2026. The company reported $403.8M in cash and $95.8M in share repurchases.
Why It Matters
Jazz's FDA acceptance for zanidatamab and Breakthrough Therapy Designation boosts its market potential and investor confidence, signaling growth in oncology and strong cash reserves for strategic initiatives.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ZYME Stock
What is Zymeworks Inc.'s (ZYME) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Zymeworks Inc. (ZYME) has a median price target of $35.00. The highest price target is $58.00 and the lowest is $28.00.
Is ZYME stock a good investment in 2026?
According to current analyst ratings, ZYME has 14 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $23.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZYME stock?
Wall Street analysts predict ZYME stock could reach $35.00 in the next 12 months. This represents a 50.5% increase from the current price of $23.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zymeworks Inc.'s business model?
Zymeworks Inc. operates by innovating and developing novel multifunctional therapeutics that address unmet medical needs in oncology and immunology. The company generates revenue through strategic partnerships with leading pharmaceutical companies, leveraging its proprietary technologies to create advanced biotherapeutics that improve treatment efficacy and reduce side effects.
What is the highest forecasted price for ZYME Zymeworks Inc.?
Price targets from Wall Street analysts for ZYME are not currently available. The stock is trading at $23.26.
What is the lowest forecasted price for ZYME Zymeworks Inc.?
The lowest price target for ZYME is $28.00 from Andrew Berens at SVB Leerink, which represents a 20.4% increase from the current price of $23.26.
What is the overall ZYME consensus from analysts for Zymeworks Inc.?
The overall analyst consensus for ZYME is bullish. Out of 11 Wall Street analysts, 14 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are ZYME stock price projections?
Stock price projections, including those for Zymeworks Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 9:36 AM UTC